May 22, 2017 - Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.
May 17, 2017 - New Strong Buy Stocks for May 17th
May 05, 2017 - Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
Apr 04, 2017 - Addus HomeCare has demographics shifting in its favor. The company has a well grounded balance sheet and room to grow. Its small market cap and nonexistent trade volume suggest it is underfollowed.
Apr 03, 2017 - Changing demographics, business dynamics, and increasing focus on containing healthcare costs are key growth drivers for Addus HomeCare.Dual eligibles segment is a strong growth opportunity for the co
Mar 29, 2017 - Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.
Mar 28, 2017 - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Mar 28, 2017 - VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
Mar 24, 2017 - Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Mar 23, 2017 - Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.